IMIDomics proudly announces the addition of Dr. Eric Perakslis, a highly accomplished pharmaceutical R&D and digital sciences executive, as Senior Vice President and Chief Technology Officer (CTO).
SAN RAFAEL, Calif.--(BUSINESS WIRE)-- IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), proudly announces the addition of Dr. Eric Perakslis, a highly accomplished pharmaceutical R&D and digital sciences executive, as Senior Vice President and Chief Technology Officer (CTO). In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science. These additions will play a pivotal role in advancing IMIDomics’ mission to accelerate data-driven drug discovery and development aimed at treating IMID patients.
Dr. Perakslis brings over two decades of experience in research, digital innovation, data science and technology leadership to IMIDomics. With a strong track record of leading implementation of digital and data strategies in healthcare, he most recently served as the Chief Science and Digital Officer at Duke Clinical Research Institute. His extensive career also includes significant leadership roles at Datavant, Takeda and J&J during his seventeen-year tenure in the pharmaceutical industry. Additionally, Dr. Perakslis spent two years as the Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration. His expertise in leveraging data analytics, machine learning, and artificial intelligence will be invaluable to advancing IMIDomics’ research and development efforts. Dr. Perakslis’ appointment aligns seamlessly with his separate role as Chief Scientific and Data Officer at Pluto Health, a tech-enabled service coordination platform.
Dr. Perakslis expressed his enthusiasm about joining IMIDomics, stating, “I am eager to work closely with the IMIDomics team and contribute to their groundbreaking work in IMIDs. The potential to transform the lives of patients through personalized medicine is immense, and I am committed to offering my knowledge and experience to support IMIDomics’ mission.”
In addition to Eric’s appointment, IMIDomics welcomes Dr. Ramon Felciano, an industry leader in applying artificial intelligence and data science to healthcare and life science challenges as a strategic advisor. Dr. Felciano is the Founder and CEO of Digital Alchemy, founded and served as CTO and VP Data Strategy for QIAGEN’s Digital Insights business, and founded Ingenuity Systems, a market leader in predictive systems biology before its acquisition by QIAGEN. Dr. Felciano brings two decades of experience applying data science and artificial intelligence to drug discovery, precision medicine, public health and biomedical research. His insights will be instrumental in guiding IMIDomics’ strategy for translational research and use of human clinicogenomic data to ensure the company remains at the forefront of the field.
“We are thrilled to welcome Dr. Perakslis as our new CTO, and Dr. Felciano as a strategic advisor,” stated Dr. Fred Craves, CEO of IMIDomics.” Their combined profound knowledge of digital technology and dedication to drug discovery and development align perfectly with our mission to develop personalized treatments for IMIDs. With Eric and Ramon on board, we are confident in our ability to expedite the pace of discovery and innovation at IMIDomics.”
About IMIDomics
IMIDomics is a biotechnology company focused on patient-centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery Engine™, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d’Hebron Institute of Research, to establish a deeper understanding of IMID diseases. IMIDomics has identified previously unrecognized targets, six of which have been selected for development within IMIDomics’ active drug pipeline. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.
To learn more about IMIDomics, please visit www.imidomics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115555092/en/
Source: IMIDomics
View this news release online at:
http://www.businesswire.com/news/home/20231115555092/en
